LinKinVax announces a collaboration with GTP BIOWAYS for the development and production of its Covid-19 vaccine

LinKinVax announces a collaboration with GTP Bioways for the development and production of its second-generation vaccine against SARS-CoV-2. GTP Bioways will manufacture clinical batches of the vaccine in Toulouse, France. This second-generation vaccine candidate targets a broader spectrum to act longer than current vaccines and against variants.

With this collaboration, the two companies are strengthening a partnership that initially focused on developing products from the VRI/INSERM vaccine platform, which LinKinVax is now exploiting under an exclusive global licence.